159 related articles for article (PubMed ID: 37596658)
1. Ideal marker for targeted axillary dissection (IMTAD): a prospective multicentre trial.
Žatecký J; Coufal O; Zapletal O; Kubala O; Kepičová M; Faridová A; Rauš K; Gatěk J; Kosáč P; Peteja M
World J Surg Oncol; 2023 Aug; 21(1):252. PubMed ID: 37596658
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
[TBL] [Abstract][Full Text] [Related]
3. Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer.
Mariscal Martínez A; Vives Roselló I; Salazar Gómez A; Catanese A; Pérez Molina M; Solà Suarez M; Pascual Miguel I; Blay Aulina L; Ríos Gozálvez C; Julián Ibáñez JF; Rodríguez Martínez P; Martínez Román S; Margelí Vila M; Luna Tomás MA
Surg Oncol; 2021 Mar; 36():28-33. PubMed ID: 33285433
[TBL] [Abstract][Full Text] [Related]
4. False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy.
de Boniface J; Frisell J; Kühn T; Wiklander-Bråkenhielm I; Dembrower K; Nyman P; Zouzos A; Gerber B; Reimer T; Hartmann S
Breast Cancer Res Treat; 2022 Jun; 193(3):589-595. PubMed ID: 35451733
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer.
Aragón-Sánchez S; Ciruelos-Gil E; López-Marín L; Galindo A; Tabuenca-Mateos MJ; Jiménez-Arranz S; Colmenero-Hernández M; Oliver-Pérez MR
Surg Oncol; 2022 Sep; 44():101823. PubMed ID: 36041377
[TBL] [Abstract][Full Text] [Related]
6. A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients.
Kuemmel S; Heil J; Rueland A; Seiberling C; Harrach H; Schindowski D; Lubitz J; Hellerhoff K; Ankel C; Graßhoff ST; Deuschle P; Hanf V; Belke K; Dall P; Dorn J; Kaltenecker G; Kuehn T; Beckmann U; Potenberg J; Blohmer JU; Kostara A; Breit E; Holtschmidt J; Traut E; Reinisch M
Ann Surg; 2022 Nov; 276(5):e553-e562. PubMed ID: 33156057
[TBL] [Abstract][Full Text] [Related]
7. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
Caudle AS; Yang WT; Krishnamurthy S; Mittendorf EA; Black DM; Gilcrease MZ; Bedrosian I; Hobbs BP; DeSnyder SM; Hwang RF; Adrada BE; Shaitelman SF; Chavez-MacGregor M; Smith BD; Candelaria RP; Babiera GV; Dogan BE; Santiago L; Hunt KK; Kuerer HM
J Clin Oncol; 2016 Apr; 34(10):1072-8. PubMed ID: 26811528
[TBL] [Abstract][Full Text] [Related]
8. SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study.
Baker JL; Haji F; Kusske AM; Fischer CP; Hoyt AC; Thompson CK; Lee MK; Attai D; DiNome ML
Breast Cancer Res Treat; 2022 Jan; 191(1):107-114. PubMed ID: 34652548
[TBL] [Abstract][Full Text] [Related]
9. Carbon nanoparticles localized clipped node dissection combined with sentinel lymph node biopsy with indocyanine green and methylene blue after neoadjuvant therapy in node positive breast cancer in China: initial results of a prospective study.
Yang X; Li Y; Ren XT; Fan L; Hua B
World J Surg Oncol; 2023 Jul; 21(1):214. PubMed ID: 37480099
[TBL] [Abstract][Full Text] [Related]
10. The importance of sentinel lymph node biopsy following neoadjuvant chemotherapy in patients with breast cancer: prospective multicentre trial.
Žatecký J; Kubala O; Coufal O; Kepičová M; Gatěk J; Prokop J; Lerch M; Peteja M
Rozhl Chir; 2021; 100(6):271-276. PubMed ID: 34465116
[TBL] [Abstract][Full Text] [Related]
11. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.
Wu SY; Li JW; Wang YJ; Jin KR; Yang BL; Li JJ; Yu XL; Mo M; Hu N; Shao ZM; Liu GY
Int J Surg; 2023 Jul; 109(7):1863-1870. PubMed ID: 37132193
[TBL] [Abstract][Full Text] [Related]
12. A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study.
van Nijnatten TJA; Simons JM; Smidt ML; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef K; Koppert LB; Luiten EJT
Clin Breast Cancer; 2017 Aug; 17(5):399-402. PubMed ID: 28487053
[TBL] [Abstract][Full Text] [Related]
13. Combined procedure of marking axillary positive node with iodine-125 seed and sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy.
Custodio Rebollo Aguirre A; Sánchez Sánchez R; González Jiménez AD; Culiañez Casas M; Mendoza Arnau I; Rashki M; Rudolphi Solero T; Martínez Meca S
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(2):75-83. PubMed ID: 31759957
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and accuracy of targeted axillary dissection in breast cancer patients; single center experience.
Kaya C; Burcu B; Çetinoğlu I; Uçak R; Çerekçi E; Şahin C; Demircioğlu ZG; Şener A; Halil S
Front Surg; 2023; 10():1332142. PubMed ID: 38269392
[TBL] [Abstract][Full Text] [Related]
15. Targeted axillary dissection with preoperative tattooing of biopsied positive axillary lymph nodes in breast cancer.
Gatek J; Petru V; Kosac P; Ratajsky M; Duben J; Dudesek B; Jancik P; Zabojnikova M; Katrusak J; Opelova P; Podrazska L; Vazan P; Kudlova P; Holik P; Melichar B; Vrana D
Neoplasma; 2020 Nov; 67(6):1329-1334. PubMed ID: 32749847
[TBL] [Abstract][Full Text] [Related]
16. The applicability of Magseed® for targeted axillary dissection in breast cancer patients treated with neoadjuvant chemotherapy.
Reitsamer R; Peintinger F; Forsthuber E; Sir A
Breast; 2021 Jun; 57():113-117. PubMed ID: 33813230
[TBL] [Abstract][Full Text] [Related]
17. Targeted axillary dissection and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy - a retrospective study.
Coufal O; Zapletal O; Gabrielová L; Fabian P; Schneiderová M
Rozhl Chir; 2018; 97(12):551-557. PubMed ID: 30646734
[TBL] [Abstract][Full Text] [Related]
18. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH
Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791
[TBL] [Abstract][Full Text] [Related]
19. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).
Boughey JC; Ballman KV; Le-Petross HT; McCall LM; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Feliberti EC; Hunt KK
Ann Surg; 2016 Apr; 263(4):802-7. PubMed ID: 26649589
[TBL] [Abstract][Full Text] [Related]
20. Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.
Diego EJ; McAuliffe PF; Soran A; McGuire KP; Johnson RR; Bonaventura M; Ahrendt GM
Ann Surg Oncol; 2016 May; 23(5):1549-53. PubMed ID: 26727919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]